Published by Josh White on 12th April 2019
(Sharecast News) - Liquid biopsy company Angle announced on Friday that a leading customer has established a multi-centre study to investigate biomarkers on circulating tumor cells (CTCs), using its 'Parsortix' system, which could give advance warning of relapse in non small cell lung cancer (NSCLC).
URL: http://www.digitallook.com/dl/news/story/28901691/...